TRC051384

TRC051384, dose dependently induces HSP70B mRNA by several hundred folds in both HeLa and rat primary mixed neurons. Treatment with TRC051384 results in significant dose-dependent increase in HSF1 transcriptional activity and recovery of luciferase activity. TRC051384 results in 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM of LPS-induced TNF-α expression in differentiated THP-1 cell line^[1].

[1]. Mohanan A, et al. Delayed intervention in experimental stroke with TRC051384--a small molecule HSP70 inducer. Neuropharmacology. 2011 May;60(6):991-9.

kailiqi Biopharma is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates.. We develop produce and distribute high quality pharmaceuticals, intermediates, special chemicals and OLED materials & OLED intermediates and other fine chemicals. Kailiqi Biopharma consists a team of professional analytical department complete QC&QA under strict SOPs, experienced sale and after-sale service, efficient logistic support. 

We are good at technology：
1.High pressure hydrogenation 
2. Low temperature reactions (-90°C) 
3. Chiral compounds by asymmetric synthesis (either chiral auxiliaries or catalysts) 
4. Small molecule biologics (e.g. non-natural amino acids, fluorinated amino acids) 
5. Green reactions (ionic liquids/fluorous chemistry)

We could give you: 
1. Best quality in your requirement 
2. Competitive price in China market 
3. Mature Technical support 
4. Professional logistic support 

All we want is win-win business. Send us your inquiries, you will get it!